SPIRIVA® Respimat® (tiotropium bromide)
SPIRIVA® Respimat® is indicated as an add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 μg budesonide/day or equivalent) and long-acting ß2 agonists and who experienced one or more severe exacerbations in the previous year.1
The content below contains references to information available within the Summary of Product Characteristics and other published sources.
SPIRIVA® Respimat® redefines what is possible by offering an additional option to help patients stay in front of asthma.
SPIRIVA® Respimat® exhibits pharmacological effects through the inhibition of M3-receptors blocking acetylcholine, which plays a significant role in the pathophysiology of asthma.2
The efficacy of adding SPIRIVA® Respimat® was studied, amongst others, in two replicate, randomised, placebo-controlled trials.
In the two PrimoTinA-asthma® trials adverse events and serious adverse events were well balanced between study groups and comparable to placebo.3
SPIRIVA® (tiotropium) is administered via the Respimat® Soft Mist™ Inhaler. Dosage, administration and instructions for use of the Respimat®inhaler are available here. Information about caring for and disposing of the inhaler are also provided.
- Summary of Product Characteristics. SPIRIVA® Respimat®. 13.01.17. Paragraph 4.1 Therapeutic indications.
- Summary of Product Characteristics. SPIRIVA® Respimat®. 13.01.17. Paragraph 5.1 Pharmacodynamic properties.
- Kerstjens H et al. N Engl J Med 2012. 367; 1198-1207.